SCHEMBL2220491

SCHEMBL2220491

N#Cc1cccc(-n2ccc(=O)c(Cc3cccc(N(CCN4CCOCC4=O)C(=O)O)c3)n2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 2/20 0.36
GRM5 P41594 1/20 0.34
F10 P00742 1/20 0.32
PIK3CD O00329 1/20 0.31
PIK3R2 O00459 1/20 0.31
PIK3CA P42336 1/20 0.31
PIK3CB P42338 1/20 0.31
PIK3CG P48736 1/20 0.31
PIK3R5 Q8WYR1 1/20 0.31
PIK3R3 Q92569 1/20 0.31
EPHX2 P34913 1/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
CASR P41180 1/20 0.30
HSP90AA1 P07900 1/20 0.30
HSP90AB1 P08238 1/20 0.30
DRD2 P14416 3/20 0.30
DRD3 P35462 3/20 0.30
KCNH2 Q12809 2/20 0.30
ROCK2 O75116 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2223914 0.90 CACNA2D1 (0.40) CACNA2D1GRM5PIK3CDPIK3R2PIK3CA
SCHEMBL2268510 0.89 CACNA2D1 (0.37) CACNA2D1GRM5NOTUM
SCHEMBL13274882 0.87 EPHX2 (0.32) EPHX2HSP90AA1HSP90AB1
SCHEMBL2262181 0.85 EPHX2 (0.33) EPHX2HSP90AA1HSP90AB1
SCHEMBL2275507 0.84 CACNA2D1 (0.40) CACNA2D1GRM5NOTUM
SCHEMBL2365417 0.83 CACNA2D1 (0.38) CACNA2D1GRM5DRD2DRD3KCNH2
SCHEMBL2365418 0.83 CACNA2D1 (0.38) CACNA2D1GRM5DRD2DRD3KCNH2
SCHEMBL2220317 0.83 GRM5 (0.38) CACNA2D1GRM5NOTUM
SCHEMBL13275128 0.81 CACNA2D1 (0.41) CACNA2D1GRM5NOTUM
SCHEMBL13274671 0.81 GRM5 (0.39) CACNA2D1GRM5NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2515657-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-10-31 EP claimed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US claimed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
WO-2011084402-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264735-A1 TYROSINE KINASE INHIBITORS ABL1, MET, ERBB2 CACNA2D1 4542/4885GRM5 1161/4885F10 4703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.